BridgeMD
New treatment option for Parkinson Disease
Official title SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease
ClinicalTrials.gov ID: NCT05765110
What this study is testing
- What it's testing
- With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect motor, emotional, and cognitive fluctuations in Parkinson's disease patients.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 75. Healthy volunteers may be eligible.
You may be able to join if
- Patients with Parkinson's Disease
- Written informed consent
- Idiopathic PD according to the Movement Disorders Society Criteria;
- Age of participants \> 30 and ≤ 75 years;
- Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;
You likely can't join if
- Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);
- Clinical diagnosis of aphasia;
- Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke...
- Cognitive impairment (Montreal Cognitive Assessment (MoCa) \< 24/30 points);
- Depression with acute suicidal ideation Healthy Controls Inclusion Criteria:
- Written informed consent
See the full eligibility criteria
- Patients with Parkinson's Disease
- Written informed consent
- Idiopathic PD according to the Movement Disorders Society Criteria;
- Age of participants \> 30 and ≤ 75 years;
- Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;
- Fluent in German or French
- Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);
- Clinical diagnosis of aphasia;
- Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).
- Cognitive impairment (Montreal Cognitive Assessment (MoCa) \< 24/30 points);
- Depression with acute suicidal ideation Healthy Controls Inclusion Criteria:
- Written informed consent
- Adults from 50-70 years old;
- Fluent in German or French Exclusion Criteria:
- Diagnosis of Parkinson's disease;
- Cognitive impairment (Montreal Cognitive Assessment (MoCa) \< 24/30 points);
- Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.);
- Clinical diagnosis of aphasia, dysarthria, and stuttering;
- Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria
The study team makes the final eligibility decision.
Where it's taking place
- Prague, Czechia
- Bern, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 75 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Prague, Czechia; Bern, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.